-

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference

Tuesday, June 3rd at 11:00 a.m. EDT

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Group’s virtual conference:

2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow

 

Hosted by:

Maxim Group LLC

Date:

June 3rd – 5th

Presentation Time:

Tuesday, June 3rd at 11:00AM EDT

Location:

Virtual (M-Vest Platform)

Registration:

Click here to register

The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT, business solutions, gaming & entertainment, and more. In Maxim’s 2025 Virtual Tech Conference, we will explore how emerging growth companies are expanding their use of Quantum Computing and Artificial Intelligence (AI) to position themselves for the future. Maxim Senior Analysts will facilitate engaging dialogues with CEOs and key management of diverse companies who have their attention on technology and how it will impact and grow their business.

This conference will be live on M-Vest. To attend, sign up to become an M-Vest member in the above registration link.

About Maxim Group LLC

Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit maximgrp.com

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Contacts

Investor Relations Contact
Louie Toma, CPA, CFA
Managing Director
www.coreir.com
investors@ipatherapeutics.com

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA

Release Versions
$Cashtags

Contacts

Investor Relations Contact
Louie Toma, CPA, CFA
Managing Director
www.coreir.com
investors@ipatherapeutics.com

Social Media Profiles
More News From ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Ral...

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA’s patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. “It’s generally assumed that AI can only m...

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also...
Back to Newsroom